vx-745 has been researched along with birb 796 in 14 studies
| Studies (vx-745) | Trials (vx-745) | Recent Studies (post-2010) (vx-745) | Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) |
|---|---|---|---|---|---|
| 58 | 1 | 35 | 137 | 5 | 80 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Boman, E; Ceide, SC; Chang, CD; Dahl, R; Dalesandro, D; Delaet, NG; Erb, E; Ernst, JT; Gibbs, A; Kahl, J; Kessler, L; Larson, CJ; Lundström, J; Miller, S; Montalban, AG; Nakanishi, H; Roberts, E; Saiah, E; Sullivan, R; Wang, Z | 1 |
| Balagué, C; Caturla, F; Domínguez, M; Esteve, C; Godessart, N; Huerta, JM; Lumeras, W; Orellana, A; Roca, R; Vidal, B; Vidal, L | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Balagué, C; Caturla, F; Domínguez, M; Lumeras, W; Maldonado, M; Orellana, A; Segarra, V; Vidal, B; Vidal, L | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Asano, T; Harayama, Y; Kasahara, C; Kinoshita, T; Kontani, T; Kubota, H; Misumi, K; Mizuhara, H; Ohno, K; Ohta, M; Takeuchi, M; Yamazaki, H; Yokomoto, M | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cahya, S; Cummins, DJ; Gao, C; Iversen, PW; Nicolaou, CA; Vieth, M; Wang, J; Watson, IA | 1 |
| Anderson, WF; Arancio, O; Chico, LW; Minasov, G; Pelletier, JC; Roy, SM; Van Eldik, LJ; Watterson, DM | 1 |
| Genovese, MC | 1 |
| Dastidar, SG; Diwan, M; Najmi, AK; Singh, RK | 1 |
1 review(s) available for vx-745 and birb 796
| Article | Year |
|---|---|
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
Topics: Animals; Brain; Cognitive Dysfunction; Humans; Inflammation; Nervous System Diseases; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors | 2019 |
13 other study(ies) available for vx-745 and birb 796
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Topics: Adenosine Triphosphate; Allosteric Site; Amides; Animals; Binding Sites; Cells, Cultured; Crystallography, X-Ray; Drug Design; Humans; Lipopolysaccharides; Models, Molecular; Molecular Structure; Monocytes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2008 |
Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Topics: Aminopyridines; Animals; Arthritis, Experimental; Catalytic Domain; Cell Line; Drug Design; Humans; Inhibitory Concentration 50; Male; Models, Molecular; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Rats; Rats, Wistar; Structure-Activity Relationship; Substrate Specificity; Tumor Necrosis Factor-alpha | 2009 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites; Cell Line; Crystallography, X-Ray; Humans; Inflammation; Lipopolysaccharides; Male; Mice; Microsomes, Liver; Monocytes; Naphthyridines; p38 Mitogen-Activated Protein Kinases; Protein Binding; Protein Conformation; Rats; Rats, Wistar; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.
Topics: Biological Availability; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Selectivity data: assessment, predictions, concordance, and implications.
Topics: Computer Simulation; Drug Discovery | 2013 |
Inhibition of p38: has the fat lady sung?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Indoles; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Pyrazoles; Pyridazines; Pyridones; Pyrimidines; Rheumatology | 2009 |
Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
Topics: Anti-Inflammatory Agents; Biomarkers; Cell Survival; Cells, Cultured; Cytokines; Hep G2 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inflammation; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; MAP Kinase Kinase 4; Naphthalenes; Nitric Oxide; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; THP-1 Cells; U937 Cells | 2018 |